Baper personal page - To The Moon

Baper

No personal profile

87Follow

8Followers

0Topic

0Badge

2021-08-17

Holding…

2021-03-29

Hello

RLX rose more than 11%

2021-03-26

Hello

Small-Cap Stocks Have Gotten Hammered. Why It’s Time to Buy the Dip.

2021-03-25

Hello

Sorry, the original content has been removed

2021-03-20

✌?✌?✌?✌?✌?

2021-03-19

Hi

Sorry, the original content has been removed

2021-03-16

Wowww

2021-03-16

Hola

Stocks That Could Benefit as the U.S. Tries to Fix the Chip Shortage

2021-03-15

Hiello

Why Eli Lilly's Successful Alzheimer's Disease Study Was So Disappointing

2021-03-12

?????

2021-03-12

Hiiiii

Sorry, the original content has been removed

2021-03-11

??????????

2021-03-11

Hello

OPEC expects most of 2021 oil demand recovery in second half

2021-03-10

Hellooo

Sorry, the original content has been removed

2021-03-09

$Oragenics(OGEN)$?????

2021-03-09

Hello

Sorry, the original content has been removed

2021-03-09

$GameStop(GME)$Gme is rising agn

2021-03-08

??????

2021-03-08

Like

Sorry, the original content has been removed

2021-03-08

Hello

Sorry, the original content has been removed

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3574683709420484","uuid":"3574683709420484","gmtCreate":1611589685637,"gmtModify":1611589685637,"name":"Baper","pinyin":"baper","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":8,"headSize":87,"tweetSize":0,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.07.19","exceedPercentage":"80.98%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.03.06","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.04%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":1,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":833978483,"gmtCreate":1629201807842,"gmtModify":1676529963915,"author":{"id":"3574683709420484","authorId":"3574683709420484","name":"Baper","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574683709420484","authorIdStr":"3574683709420484"},"themes":[],"htmlText":"Holding…","listText":"Holding…","text":"Holding…","images":[{"img":"https://static.tigerbbs.com/97b09c1f84431de61432dcdb15d171a4","width":"1125","height":"2793"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/833978483","isVote":1,"tweetType":1,"viewCount":2433,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":355334406,"gmtCreate":1617027949005,"gmtModify":1704801077052,"author":{"id":"3574683709420484","authorId":"3574683709420484","name":"Baper","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574683709420484","authorIdStr":"3574683709420484"},"themes":[],"htmlText":"Hello","listText":"Hello","text":"Hello","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/355334406","repostId":"1161842003","repostType":4,"repost":{"id":"1161842003","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1617027210,"share":"https://ttm.financial/m/news/1161842003?lang=en_US&edition=fundamental","pubTime":"2021-03-29 22:13","market":"us","language":"en","title":"RLX rose more than 11%","url":"https://stock-news.laohu8.com/highlight/detail?id=1161842003","media":"Tiger Newspress","summary":"(March 29) Days ago, China's Ministry of Industry and Information Technology posted an update that i","content":"<p>(March 29)&nbsp;Days ago, China's Ministry of Industry and Information Technology posted an update that indicated tightened regulations for the cigarette industry will also be applicable to the electronic cigarette sector.</p><p><img src=\"https://static.tigerbbs.com/30359e8f873abb547c80ebb67d0b3d90\" tg-width=\"642\" tg-height=\"512\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RLX rose more than 11%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRLX rose more than 11%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-03-29 22:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(March 29)&nbsp;Days ago, China's Ministry of Industry and Information Technology posted an update that indicated tightened regulations for the cigarette industry will also be applicable to the electronic cigarette sector.</p><p><img src=\"https://static.tigerbbs.com/30359e8f873abb547c80ebb67d0b3d90\" tg-width=\"642\" tg-height=\"512\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/9bc4ee269ad9cff7441dc3605e3bc69a","relate_stocks":{"RLX":"雾芯科技"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1161842003","content_text":"(March 29) Days ago, China's Ministry of Industry and Information Technology posted an update that indicated tightened regulations for the cigarette industry will also be applicable to the electronic cigarette sector.","news_type":1,"symbols_score_info":{"RLX":0.9}},"isVote":1,"tweetType":1,"viewCount":2978,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":356932672,"gmtCreate":1616747796996,"gmtModify":1704798264398,"author":{"id":"3574683709420484","authorId":"3574683709420484","name":"Baper","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574683709420484","authorIdStr":"3574683709420484"},"themes":[],"htmlText":"Hello","listText":"Hello","text":"Hello","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/356932672","repostId":"1197336093","repostType":4,"repost":{"id":"1197336093","kind":"news","pubTimestamp":1616747282,"share":"https://ttm.financial/m/news/1197336093?lang=en_US&edition=fundamental","pubTime":"2021-03-26 16:28","market":"us","language":"en","title":"Small-Cap Stocks Have Gotten Hammered. Why It’s Time to Buy the Dip.","url":"https://stock-news.laohu8.com/highlight/detail?id=1197336093","media":"Barrons","summary":"Small-cap stocks have taken a beating in the past few days, in an abrupt turnaround from their exten","content":"<p>Small-cap stocks have taken a beating in the past few days, in an abrupt turnaround from their extended rally. But this quite possibly is a chance for investors to scoop up small-caps ahead of a longer-term rebound.</p>\n<p>The Russell 2000 has fallen almost 10% from its 2021 high hit just 10 days ago—putting it on pace to enter correction territory.</p>\n<p>Small-capitalization stocks had been on animpressive run since September, when investors started moving intomore economically-sensitive assetson hopes for an end to the pandemic and the reopening of the U.S. economy—plus trillions of dollars in fiscal stimulus. Economic downturns are a bigger threat to the stability of smaller firms, since they don’t have the same access to capital that larger companies enjoy. And with many small-cap companies focused on the U.S. market, their earnings also tend to be more sensitive tochanges in the domestic economic landscape.</p>\n<p>In recent days, investors have been repositioning away from cyclical stocksafter the group’s long winning streak, and small-caps have been no exception. While it is anybody’s guess when this pullback will end, small-cap stocks are looking increasingly attractive to some analysts as a result.</p>\n<p>“We prefer small-caps for the year as a whole, would ride out any short-term underperformance,” Lori Calvasina, chief U.S. equity strategist of RBC Capital Markets, wrote in a Wednesday note.</p>\n<p>Currently, the average market value for theRussell 1000index—which consists of large and smaller capitalization stocks—is about $39 billion. That’s 23 times as large as the average market cap on the Russell 2000, according to RBC data. That metric’s historical average, dating back to 2000, is 21 times. The wider gap between the average market cap suggests that small-caps have more outperformance versus large-caps ahead, especially as they ride earnings momentum from a U.S. economic recovery.</p>\n<p>The Russell 2000’s technical indicators also point to strength ahead for smaller names. The index dipped below its 50-day moving average on Tuesday, and it “has seen many of its best rallies start after such an occurrence,” wrote Frank Cappelleri, chief market technician at Instinet in a note.</p>\n<p>Within small-caps, value stocks might be the best subset for buying the dip. Value-oriented companies are typically more mature companies, so their earnings can be more sensitive to changes in the economy than those of fast-growing companies capitalizing on new industry trends.</p>\n<p>Oil producerDiamondback Energy(ticker: FANG), which has a market capitalization of $13 billion, is a good example of the opportunity in small-cap value. Its shares have fallen about 15% from the 2021 high hit earlier this month. The stock trades at 9 times forward earnings, a steep discount to the Russell 2000 Value index’s 21.5 times.</p>\n<p>Diamondback stock has been about a third more volatile than the broader market, according to FactSet. That means any gains for larger value names could translate to even more upside to smaller value names like Diamondback. That’s especially true if the price of crude oil can get back to $65 a barrel from the current level of $60. In addition, the company’s earnings are expected to more than double this year, and are forecast to grow almost 30% in 2022, according to FactSet. The stock, however, barely reflects such the earnings momentum ahead: It still trades at less than half the forward earnings multiple it has averaged in the past five years.</p>\n<p>In order for the broader group of small-cap stocks to regain momentum, however, their valuations have to be tolerable, too. The latest pullback should help with that.</p>\n<p>In addition, RBC’s Calvasina points out that these stocks already remain “deeply compelling” from a valuation perspective when compared withS&amp;P 500stocks.</p>\n<p>“That valuation recovery is still in the early innings of a recovery off lows last seen in the tech bubble,” she writes.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Small-Cap Stocks Have Gotten Hammered. Why It’s Time to Buy the Dip.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSmall-Cap Stocks Have Gotten Hammered. Why It’s Time to Buy the Dip.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-26 16:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/small-cap-stocks-correction-russell-2000-51616686761?mod=hp_LEAD_5><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Small-cap stocks have taken a beating in the past few days, in an abrupt turnaround from their extended rally. But this quite possibly is a chance for investors to scoop up small-caps ahead of a ...</p>\n\n<a href=\"https://www.barrons.com/articles/small-cap-stocks-correction-russell-2000-51616686761?mod=hp_LEAD_5\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index"},"source_url":"https://www.barrons.com/articles/small-cap-stocks-correction-russell-2000-51616686761?mod=hp_LEAD_5","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197336093","content_text":"Small-cap stocks have taken a beating in the past few days, in an abrupt turnaround from their extended rally. But this quite possibly is a chance for investors to scoop up small-caps ahead of a longer-term rebound.\nThe Russell 2000 has fallen almost 10% from its 2021 high hit just 10 days ago—putting it on pace to enter correction territory.\nSmall-capitalization stocks had been on animpressive run since September, when investors started moving intomore economically-sensitive assetson hopes for an end to the pandemic and the reopening of the U.S. economy—plus trillions of dollars in fiscal stimulus. Economic downturns are a bigger threat to the stability of smaller firms, since they don’t have the same access to capital that larger companies enjoy. And with many small-cap companies focused on the U.S. market, their earnings also tend to be more sensitive tochanges in the domestic economic landscape.\nIn recent days, investors have been repositioning away from cyclical stocksafter the group’s long winning streak, and small-caps have been no exception. While it is anybody’s guess when this pullback will end, small-cap stocks are looking increasingly attractive to some analysts as a result.\n“We prefer small-caps for the year as a whole, would ride out any short-term underperformance,” Lori Calvasina, chief U.S. equity strategist of RBC Capital Markets, wrote in a Wednesday note.\nCurrently, the average market value for theRussell 1000index—which consists of large and smaller capitalization stocks—is about $39 billion. That’s 23 times as large as the average market cap on the Russell 2000, according to RBC data. That metric’s historical average, dating back to 2000, is 21 times. The wider gap between the average market cap suggests that small-caps have more outperformance versus large-caps ahead, especially as they ride earnings momentum from a U.S. economic recovery.\nThe Russell 2000’s technical indicators also point to strength ahead for smaller names. The index dipped below its 50-day moving average on Tuesday, and it “has seen many of its best rallies start after such an occurrence,” wrote Frank Cappelleri, chief market technician at Instinet in a note.\nWithin small-caps, value stocks might be the best subset for buying the dip. Value-oriented companies are typically more mature companies, so their earnings can be more sensitive to changes in the economy than those of fast-growing companies capitalizing on new industry trends.\nOil producerDiamondback Energy(ticker: FANG), which has a market capitalization of $13 billion, is a good example of the opportunity in small-cap value. Its shares have fallen about 15% from the 2021 high hit earlier this month. The stock trades at 9 times forward earnings, a steep discount to the Russell 2000 Value index’s 21.5 times.\nDiamondback stock has been about a third more volatile than the broader market, according to FactSet. That means any gains for larger value names could translate to even more upside to smaller value names like Diamondback. That’s especially true if the price of crude oil can get back to $65 a barrel from the current level of $60. In addition, the company’s earnings are expected to more than double this year, and are forecast to grow almost 30% in 2022, according to FactSet. The stock, however, barely reflects such the earnings momentum ahead: It still trades at less than half the forward earnings multiple it has averaged in the past five years.\nIn order for the broader group of small-cap stocks to regain momentum, however, their valuations have to be tolerable, too. The latest pullback should help with that.\nIn addition, RBC’s Calvasina points out that these stocks already remain “deeply compelling” from a valuation perspective when compared withS&P 500stocks.\n“That valuation recovery is still in the early innings of a recovery off lows last seen in the tech bubble,” she writes.","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9}},"isVote":1,"tweetType":1,"viewCount":2384,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":358804599,"gmtCreate":1616677818011,"gmtModify":1704797289269,"author":{"id":"3574683709420484","authorId":"3574683709420484","name":"Baper","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574683709420484","authorIdStr":"3574683709420484"},"themes":[],"htmlText":"Hello","listText":"Hello","text":"Hello","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/358804599","repostId":"2122052417","repostType":4,"isVote":1,"tweetType":1,"viewCount":2580,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":350482075,"gmtCreate":1616253574897,"gmtModify":1704792496554,"author":{"id":"3574683709420484","authorId":"3574683709420484","name":"Baper","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574683709420484","authorIdStr":"3574683709420484"},"themes":[],"htmlText":"✌?✌?✌?✌?✌?","listText":"✌?✌?✌?✌?✌?","text":"✌?✌?✌?✌?✌?","images":[{"img":"https://static.tigerbbs.com/4a73c817b795ac5bbaf0e8e0e4b05db8","width":"1125","height":"2839"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/350482075","isVote":1,"tweetType":1,"viewCount":2878,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":327239359,"gmtCreate":1616084803771,"gmtModify":1704790859969,"author":{"id":"3574683709420484","authorId":"3574683709420484","name":"Baper","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574683709420484","authorIdStr":"3574683709420484"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/327239359","repostId":"2120165521","repostType":4,"isVote":1,"tweetType":1,"viewCount":2183,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":325343765,"gmtCreate":1615868448757,"gmtModify":1704787704597,"author":{"id":"3574683709420484","authorId":"3574683709420484","name":"Baper","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574683709420484","authorIdStr":"3574683709420484"},"themes":[],"htmlText":"Wowww","listText":"Wowww","text":"Wowww","images":[{"img":"https://static.tigerbbs.com/6d3677bbfb2da327605c68128079326f","width":"1125","height":"2374"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/325343765","isVote":1,"tweetType":1,"viewCount":2611,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":325343649,"gmtCreate":1615868396481,"gmtModify":1704787703790,"author":{"id":"3574683709420484","authorId":"3574683709420484","name":"Baper","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574683709420484","authorIdStr":"3574683709420484"},"themes":[],"htmlText":"Hola","listText":"Hola","text":"Hola","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/325343649","repostId":"1196198740","repostType":4,"repost":{"id":"1196198740","kind":"news","pubTimestamp":1615865708,"share":"https://ttm.financial/m/news/1196198740?lang=en_US&edition=fundamental","pubTime":"2021-03-16 11:35","market":"us","language":"en","title":"Stocks That Could Benefit as the U.S. Tries to Fix the Chip Shortage","url":"https://stock-news.laohu8.com/highlight/detail?id=1196198740","media":"Barrons","summary":"As the U.S. government inches closer to funding a batch of incentives and subsidies designed to spur","content":"<p>As the U.S. government inches closer to funding a batch of incentives and subsidies designed to spur domestic semiconductor manufacturing and research, aJ.P. Morgananalyst has figured out which stocks could stand to gain the most from it.</p><p>Amid global chip shortages, triggered in part by supply and demand fluctuations because of the Covid-19 pandemic as well asnatural disasters, Congress authorized a series of programs and incentives for U.S.-based chip companies earlier this year. Lawmakers included the programs designed to bolster U.S. manufacturing, research, and development in the National Defense Authorization Act for fiscal 2021, which became law in January, but didn’t provide funding for those initiatives.</p><p>According to J.P. Morgan chip analyst Harlan Sur, it’s likely that funding for those programs may be included in President Joe Biden ‘s infrastructure bill, one of the next priorities for the administration. Sur expects the “Build Back Better” infrastructure plan to pass in the first half of the year, resulting in funding starting in the second half of 2021.</p><p>Sur’s team estimated the incentives and subsidies could total between $35 billion and $37 billion, with about $18 billion to $20 billion for domestic chip manufacturing and $15 billion to $17 billion for chip research and development.</p><p>Based on the current language in the National Defense Authorize Act, Sur wrote in a note published on Monday that he expects integrated device manufacturers based in the U.S. will likely be prioritized when it’s time to dole out funds and incentives.</p><p>Those would include manufacturers such as&nbsp;Intel(ticker: INTC),Micron Technology(MU),Texas Instruments(TXN),Analog Devices(ADI), and&nbsp;On Semiconductor(ON) are all likely to benefit, Sur wrote. Companies that have U.S. defense-related qualifications are well-positioned to benefit as well, he wrote.Taiwan Semiconductor Manufacturing(TSM) and&nbsp;NXP Semiconductors(NXPI), international-based chip manufacturers that operate in the U.S., should benefit too, he said, but to a lesser degree.</p><p>Companies that make chip manufacturing equipment such as&nbsp;Applied Materials(AMAT) and&nbsp;Lam Research(LRCX) should also receive a lift because of higher equipment purchasing resulting from the incentives.</p><p>The&nbsp;PHLX Semiconductor index,or Sox, advanced about 2% on Monday, led by&nbsp;NXP Semiconductors&nbsp;NXP, which rose 8.9% to $199.91, and&nbsp;Broadcom(AVGO), which jumped 4.3% to $470.77.</p><p>The Sox has gained 94% in the past year as&nbsp;demand for chips&nbsp;destined for productsranging from appliancesand videogame consoles to vehicles and smartphones has outpaced the industry’s ability to produce semiconductors.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stocks That Could Benefit as the U.S. Tries to Fix the Chip Shortage</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStocks That Could Benefit as the U.S. Tries to Fix the Chip Shortage\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-16 11:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/the-u-s-is-trying-to-fix-the-chip-shortage-what-it-could-mean-for-semiconductor-stocks-51615838286?mod=hp_LATEST><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As the U.S. government inches closer to funding a batch of incentives and subsidies designed to spur domestic semiconductor manufacturing and research, aJ.P. Morgananalyst has figured out which stocks...</p>\n\n<a href=\"https://www.barrons.com/articles/the-u-s-is-trying-to-fix-the-chip-shortage-what-it-could-mean-for-semiconductor-stocks-51615838286?mod=hp_LATEST\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ON":"安森美半导体","MU":"美光科技","INTC":"英特尔","TXN":"德州仪器","TSM":"台积电","ADI":"亚德诺","NXPI":"恩智浦"},"source_url":"https://www.barrons.com/articles/the-u-s-is-trying-to-fix-the-chip-shortage-what-it-could-mean-for-semiconductor-stocks-51615838286?mod=hp_LATEST","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1196198740","content_text":"As the U.S. government inches closer to funding a batch of incentives and subsidies designed to spur domestic semiconductor manufacturing and research, aJ.P. Morgananalyst has figured out which stocks could stand to gain the most from it.Amid global chip shortages, triggered in part by supply and demand fluctuations because of the Covid-19 pandemic as well asnatural disasters, Congress authorized a series of programs and incentives for U.S.-based chip companies earlier this year. Lawmakers included the programs designed to bolster U.S. manufacturing, research, and development in the National Defense Authorization Act for fiscal 2021, which became law in January, but didn’t provide funding for those initiatives.According to J.P. Morgan chip analyst Harlan Sur, it’s likely that funding for those programs may be included in President Joe Biden ‘s infrastructure bill, one of the next priorities for the administration. Sur expects the “Build Back Better” infrastructure plan to pass in the first half of the year, resulting in funding starting in the second half of 2021.Sur’s team estimated the incentives and subsidies could total between $35 billion and $37 billion, with about $18 billion to $20 billion for domestic chip manufacturing and $15 billion to $17 billion for chip research and development.Based on the current language in the National Defense Authorize Act, Sur wrote in a note published on Monday that he expects integrated device manufacturers based in the U.S. will likely be prioritized when it’s time to dole out funds and incentives.Those would include manufacturers such as Intel(ticker: INTC),Micron Technology(MU),Texas Instruments(TXN),Analog Devices(ADI), and On Semiconductor(ON) are all likely to benefit, Sur wrote. Companies that have U.S. defense-related qualifications are well-positioned to benefit as well, he wrote.Taiwan Semiconductor Manufacturing(TSM) and NXP Semiconductors(NXPI), international-based chip manufacturers that operate in the U.S., should benefit too, he said, but to a lesser degree.Companies that make chip manufacturing equipment such as Applied Materials(AMAT) and Lam Research(LRCX) should also receive a lift because of higher equipment purchasing resulting from the incentives.The PHLX Semiconductor index,or Sox, advanced about 2% on Monday, led by NXP Semiconductors NXP, which rose 8.9% to $199.91, and Broadcom(AVGO), which jumped 4.3% to $470.77.The Sox has gained 94% in the past year as demand for chips destined for productsranging from appliancesand videogame consoles to vehicles and smartphones has outpaced the industry’s ability to produce semiconductors.","news_type":1,"symbols_score_info":{"INTC":0.9,"TXN":0.9,"ADI":0.9,"MU":0.9,"ON":0.9,"TSM":0.9,"NXPI":0.9}},"isVote":1,"tweetType":1,"viewCount":3001,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":322487202,"gmtCreate":1615820904706,"gmtModify":1704787125354,"author":{"id":"3574683709420484","authorId":"3574683709420484","name":"Baper","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574683709420484","authorIdStr":"3574683709420484"},"themes":[],"htmlText":"Hiello","listText":"Hiello","text":"Hiello","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/322487202","repostId":"1110886827","repostType":4,"repost":{"id":"1110886827","kind":"news","pubTimestamp":1615819641,"share":"https://ttm.financial/m/news/1110886827?lang=en_US&edition=fundamental","pubTime":"2021-03-15 22:47","market":"us","language":"en","title":"Why Eli Lilly's Successful Alzheimer's Disease Study Was So Disappointing","url":"https://stock-news.laohu8.com/highlight/detail?id=1110886827","media":"Motley Fool","summary":"Eli Lilly's latest Alzheimer's disease candidate is a terrific success and a disappointing flop at t","content":"<blockquote><b>Eli Lilly's latest Alzheimer's disease candidate is a terrific success and a disappointing flop at the same time.</b></blockquote><p>Attention for<b>Eli Lilly</b>(NYSE:LLY)has been blowing up since the company announced success for its experimental new Alzheimer's disease drug. Unfortunately, the results strongly suggest that Eli Lilly and<b>Biogen</b>(NASDAQ:BIIB)have a lot more work to do.</p><p>How can a clinical trial that succeeded also foreshadow a slow-motion trainwreck? Strap in for some nuance.</p><p><b>Technically a success</b></p><p>The phase 2 Trailblazer trial rounded up hundreds of people with early stage Alzheimer's disease and treated them with either a placebo or donanemab to see if the experimental antibody could prevent their disease from getting worse.</p><p>Earlier this year, Eli Lilly sparked a lot of hope for donanemab by telling everybody the Trailblazer trial met its main goal. That goal was a significantly improved score on a relatively new test to measure patients' cognitive and functional abilities. After treating 257 patients for 76 weeks, test scores for those given a placebo deteriorated 46% further than test scores for patients randomized to receive donanemab.</p><p>Donanemab works in the brain to reduce the formation of dangerous plaques made of amyloid protein fragments. After 76 weeks, comparing brain scans also showed huge amyloid plaque reductions for those given donanemab compared to those given a placebo.</p><p><b>Why donanemab disappointed</b></p><p>Donanemab significantly slowed patients' rate of decline on the integrated Alzheimer's disease rating scale. The iADRS combines a commonly used cognition test with a test that measures AD patients' ability to function as adults.</p><p>The FDA has never reviewed an application for a potential new Alzheimer's disease drug based on a successful iADRS score. That could be a big problem for Eli Lilly because the Trailblazer study assaulted trial participants with a battery of different tests and the iADRS was the only measurement in which donanemab provided a statistically significant benefit.</p><p>Moreover, the benefit wasn't any better than Eli Lilly reported for solanezumab years ago. This twice-failed amyloid remover from Eli Lilly couldn't meet its primary endpoint in phase 3 trials, but it did lead to significantly improved iADRS scores.</p><p><b>This isn't working</b></p><p>Donanemab is similar to solanezumab, except it appears far more effective at removing amyloid deposits and preventing their formation. This is why Eli Lilly was eager to make the iADRS test aprimary endpointfor donanemab trials, and extra careful to select trial volunteers that already had lots of amyloid deposits to remove.</p><p>If the donanemab program went according to plan, more amyloid to remove, plus a better drug to remove it should have led to an iADRS score benefit that rang clear as a bell. What happened was far less satisfying.</p><p>Patients began the Trailblazer trial with average iADRS scores of 106 points out of a potential 141 points. After 76 weeks, those given a placebo averaged just 3.2 points lower than those given donanemab.</p><p>Unfortunately, those given donanemab didn't improve or even hold steady. In fact, their average scores fell by 6.9 points.</p><p><b>What's next</b></p><p>The Trailblazer trial is another clear sign that removing amyloid deposits isn't a surefire way to stop the progression of AD, but it appears to work well for some. Decades from now we'll probably think of AD as a collection of different diseases, just one or two of which respond to drugs like donanemab on their own. In the meantime, U.S. regulators have a controversial decision to make that could help us understand the connection between amyloid knockdowns and the disease.</p><p>The FDA iseager to approvean amyloid-clearing AD drug from Biogen called aducanumab even though independent experts unanimously agree that pivotal trial results didn't show evidence of a benefit. If approved, widespread adoption of Biogen's drug could elucidate just which AD patients respond well to amyloid knockdowns and which don't. The line between Biogen's and Eli Lilly's attempts to treat AD isn't a straight one, but donanemab's future depends on the FDA's willingness to bend the rules for aducanumab.</p><p>Alzheimer's disease affects one out of nine adults over the age of 65 and a dearth of available treatments means the first one will become one of the top-selling drugs of its time. With such an enormous pot of gold at the end of this rainbow, we can't fault Eli Lilly for making further attempts with donanemab. Unfortunately, its chances of success don't look very good.</p><p>Lilly dipped more than 8%&nbsp;in&nbsp;Monday&nbsp;trading.<img src=\"https://static.tigerbbs.com/d7574b908a909fcd58830836a11eb2fc\" tg-width=\"724\" tg-height=\"495\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Eli Lilly's Successful Alzheimer's Disease Study Was So Disappointing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Eli Lilly's Successful Alzheimer's Disease Study Was So Disappointing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-15 22:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/03/15/eli-lilly-reports-underwhelming-alzheimers-disease/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Eli Lilly's latest Alzheimer's disease candidate is a terrific success and a disappointing flop at the same time.Attention forEli Lilly(NYSE:LLY)has been blowing up since the company announced success...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/15/eli-lilly-reports-underwhelming-alzheimers-disease/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来"},"source_url":"https://www.fool.com/investing/2021/03/15/eli-lilly-reports-underwhelming-alzheimers-disease/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1110886827","content_text":"Eli Lilly's latest Alzheimer's disease candidate is a terrific success and a disappointing flop at the same time.Attention forEli Lilly(NYSE:LLY)has been blowing up since the company announced success for its experimental new Alzheimer's disease drug. Unfortunately, the results strongly suggest that Eli Lilly andBiogen(NASDAQ:BIIB)have a lot more work to do.How can a clinical trial that succeeded also foreshadow a slow-motion trainwreck? Strap in for some nuance.Technically a successThe phase 2 Trailblazer trial rounded up hundreds of people with early stage Alzheimer's disease and treated them with either a placebo or donanemab to see if the experimental antibody could prevent their disease from getting worse.Earlier this year, Eli Lilly sparked a lot of hope for donanemab by telling everybody the Trailblazer trial met its main goal. That goal was a significantly improved score on a relatively new test to measure patients' cognitive and functional abilities. After treating 257 patients for 76 weeks, test scores for those given a placebo deteriorated 46% further than test scores for patients randomized to receive donanemab.Donanemab works in the brain to reduce the formation of dangerous plaques made of amyloid protein fragments. After 76 weeks, comparing brain scans also showed huge amyloid plaque reductions for those given donanemab compared to those given a placebo.Why donanemab disappointedDonanemab significantly slowed patients' rate of decline on the integrated Alzheimer's disease rating scale. The iADRS combines a commonly used cognition test with a test that measures AD patients' ability to function as adults.The FDA has never reviewed an application for a potential new Alzheimer's disease drug based on a successful iADRS score. That could be a big problem for Eli Lilly because the Trailblazer study assaulted trial participants with a battery of different tests and the iADRS was the only measurement in which donanemab provided a statistically significant benefit.Moreover, the benefit wasn't any better than Eli Lilly reported for solanezumab years ago. This twice-failed amyloid remover from Eli Lilly couldn't meet its primary endpoint in phase 3 trials, but it did lead to significantly improved iADRS scores.This isn't workingDonanemab is similar to solanezumab, except it appears far more effective at removing amyloid deposits and preventing their formation. This is why Eli Lilly was eager to make the iADRS test aprimary endpointfor donanemab trials, and extra careful to select trial volunteers that already had lots of amyloid deposits to remove.If the donanemab program went according to plan, more amyloid to remove, plus a better drug to remove it should have led to an iADRS score benefit that rang clear as a bell. What happened was far less satisfying.Patients began the Trailblazer trial with average iADRS scores of 106 points out of a potential 141 points. After 76 weeks, those given a placebo averaged just 3.2 points lower than those given donanemab.Unfortunately, those given donanemab didn't improve or even hold steady. In fact, their average scores fell by 6.9 points.What's nextThe Trailblazer trial is another clear sign that removing amyloid deposits isn't a surefire way to stop the progression of AD, but it appears to work well for some. Decades from now we'll probably think of AD as a collection of different diseases, just one or two of which respond to drugs like donanemab on their own. In the meantime, U.S. regulators have a controversial decision to make that could help us understand the connection between amyloid knockdowns and the disease.The FDA iseager to approvean amyloid-clearing AD drug from Biogen called aducanumab even though independent experts unanimously agree that pivotal trial results didn't show evidence of a benefit. If approved, widespread adoption of Biogen's drug could elucidate just which AD patients respond well to amyloid knockdowns and which don't. The line between Biogen's and Eli Lilly's attempts to treat AD isn't a straight one, but donanemab's future depends on the FDA's willingness to bend the rules for aducanumab.Alzheimer's disease affects one out of nine adults over the age of 65 and a dearth of available treatments means the first one will become one of the top-selling drugs of its time. With such an enormous pot of gold at the end of this rainbow, we can't fault Eli Lilly for making further attempts with donanemab. Unfortunately, its chances of success don't look very good.Lilly dipped more than 8% in Monday trading.","news_type":1,"symbols_score_info":{"LLY":0.9}},"isVote":1,"tweetType":1,"viewCount":3382,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":328445474,"gmtCreate":1615555786698,"gmtModify":1704784490871,"author":{"id":"3574683709420484","authorId":"3574683709420484","name":"Baper","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574683709420484","authorIdStr":"3574683709420484"},"themes":[],"htmlText":"?????","listText":"?????","text":"?????","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/328445474","isVote":1,"tweetType":1,"viewCount":2392,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":328446245,"gmtCreate":1615555587887,"gmtModify":1704784488432,"author":{"id":"3574683709420484","authorId":"3574683709420484","name":"Baper","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574683709420484","authorIdStr":"3574683709420484"},"themes":[],"htmlText":"Hiiiii","listText":"Hiiiii","text":"Hiiiii","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/328446245","repostId":"1154730003","repostType":4,"isVote":1,"tweetType":1,"viewCount":1071,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":328047076,"gmtCreate":1615476498695,"gmtModify":1704783406152,"author":{"id":"3574683709420484","authorId":"3574683709420484","name":"Baper","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574683709420484","authorIdStr":"3574683709420484"},"themes":[],"htmlText":"??????????","listText":"??????????","text":"??????????","images":[{"img":"https://static.tigerbbs.com/1a9b4103516a91a5550df00ab510a796","width":"1125","height":"2743"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/328047076","isVote":1,"tweetType":1,"viewCount":850,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":328044804,"gmtCreate":1615476467108,"gmtModify":1704783404851,"author":{"id":"3574683709420484","authorId":"3574683709420484","name":"Baper","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574683709420484","authorIdStr":"3574683709420484"},"themes":[],"htmlText":"Hello","listText":"Hello","text":"Hello","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/328044804","repostId":"1120482093","repostType":4,"repost":{"id":"1120482093","kind":"news","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1615475560,"share":"https://ttm.financial/m/news/1120482093?lang=en_US&edition=fundamental","pubTime":"2021-03-11 23:12","market":"us","language":"en","title":"OPEC expects most of 2021 oil demand recovery in second half","url":"https://stock-news.laohu8.com/highlight/detail?id=1120482093","media":"Reuters","summary":"OPEC said on Thursday a recovery in oil demand will be focused on the second half of the year as the","content":"<p>OPEC said on Thursday a recovery in oil demand will be focused on the second half of the year as the impact of the pandemic lingers as a headwind for the group and its allies in supporting the market.</p>\n<p>In a monthly report, the Organization of the Petroleum Exporting Countries said demand will rise by 5.89 million barrels per day (bpd) in 2021, or 6.5%, up slightly from last month. But the group cut its forecasts for the first half.</p>\n<p>“Total oil demand is foreseen to reach 96.3 million bpd with most consumption appearing in the second half,” OPEC said in the report.</p>\n<p>“This year’s demand growth will not be able to compensate for the major shortfall from 2020 as mobility is forecast to remain impaired throughout 2021.”</p>\n<p>The latest forecasts could bolster cautious views among OPEC and its allies, known as OPEC+, on how quickly to unwind more of last year’s record oil output cuts. OPEC+ last week decided to mostly extend current curbs into April.</p>\n<p>Oil held onto most of an earlier gain after the report was released, trading close to $69 a barrel. Prices have risen to pre-pandemic highs this month, boosted by hopes of economic recovery and OPEC+ supply restraint.</p>\n<p>OPEC raised its forecast of world economic growth this year to 5.1% from 4.8% as activity accelerates by the end of the first half. Still, it sees the mobility restrictions continuing to dampen oil demand, despite faster growth.</p>\n<p>“Oil-intensive sectors, especially travel and transportation, will remain disproportionately affected, with a larger negative impact on 2020 oil demand and a lower positive contribution to 2021 oil demand, relative to global economic growth,” OPEC said.</p>\n<p><b>SAUDI DELIVERS CUT</b></p>\n<p>The report also showed lower OPEC oil output in February as most OPEC+ members returned to output restraint and Saudi Arabia pledged a voluntary cut of 1 million bpd for February and March.</p>\n<p>OPEC said its February output fell by 650,000 bpd to 24.85 million bpd, driven by the Saudi move. Riyadh told OPEC it made almost all of the reduction, lowering production by 956,000 bpd to 8.147 million bpd.</p>\n<p>Saudi Arabia as part of last week’s OPEC+ decision extended the voluntary cut into April.</p>\n<p>OPEC+ cut supply by a record 9.7 million bpd last year to support the market as demand collapsed. The producers as of February were still withholding about 8.1 million bpd.</p>\n<p>While those curbs persist, rivals are boosting supply and OPEC raised its forecast of non-OPEC output growth to almost 1 million bpd led by Canada, the United States, Norway and Brazil - although U.S. shale output is still expected to drop.</p>\n<p>Partly due to the higher non-OPEC supply forecast, OPEC trimmed its estimate of global demand for its crude to 27.3 million bpd this year. This would still allow for higher average OPEC production in 2021.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>OPEC expects most of 2021 oil demand recovery in second half</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOPEC expects most of 2021 oil demand recovery in second half\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-03-11 23:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>OPEC said on Thursday a recovery in oil demand will be focused on the second half of the year as the impact of the pandemic lingers as a headwind for the group and its allies in supporting the market.</p>\n<p>In a monthly report, the Organization of the Petroleum Exporting Countries said demand will rise by 5.89 million barrels per day (bpd) in 2021, or 6.5%, up slightly from last month. But the group cut its forecasts for the first half.</p>\n<p>“Total oil demand is foreseen to reach 96.3 million bpd with most consumption appearing in the second half,” OPEC said in the report.</p>\n<p>“This year’s demand growth will not be able to compensate for the major shortfall from 2020 as mobility is forecast to remain impaired throughout 2021.”</p>\n<p>The latest forecasts could bolster cautious views among OPEC and its allies, known as OPEC+, on how quickly to unwind more of last year’s record oil output cuts. OPEC+ last week decided to mostly extend current curbs into April.</p>\n<p>Oil held onto most of an earlier gain after the report was released, trading close to $69 a barrel. Prices have risen to pre-pandemic highs this month, boosted by hopes of economic recovery and OPEC+ supply restraint.</p>\n<p>OPEC raised its forecast of world economic growth this year to 5.1% from 4.8% as activity accelerates by the end of the first half. Still, it sees the mobility restrictions continuing to dampen oil demand, despite faster growth.</p>\n<p>“Oil-intensive sectors, especially travel and transportation, will remain disproportionately affected, with a larger negative impact on 2020 oil demand and a lower positive contribution to 2021 oil demand, relative to global economic growth,” OPEC said.</p>\n<p><b>SAUDI DELIVERS CUT</b></p>\n<p>The report also showed lower OPEC oil output in February as most OPEC+ members returned to output restraint and Saudi Arabia pledged a voluntary cut of 1 million bpd for February and March.</p>\n<p>OPEC said its February output fell by 650,000 bpd to 24.85 million bpd, driven by the Saudi move. Riyadh told OPEC it made almost all of the reduction, lowering production by 956,000 bpd to 8.147 million bpd.</p>\n<p>Saudi Arabia as part of last week’s OPEC+ decision extended the voluntary cut into April.</p>\n<p>OPEC+ cut supply by a record 9.7 million bpd last year to support the market as demand collapsed. The producers as of February were still withholding about 8.1 million bpd.</p>\n<p>While those curbs persist, rivals are boosting supply and OPEC raised its forecast of non-OPEC output growth to almost 1 million bpd led by Canada, the United States, Norway and Brazil - although U.S. shale output is still expected to drop.</p>\n<p>Partly due to the higher non-OPEC supply forecast, OPEC trimmed its estimate of global demand for its crude to 27.3 million bpd this year. This would still allow for higher average OPEC production in 2021.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1120482093","content_text":"OPEC said on Thursday a recovery in oil demand will be focused on the second half of the year as the impact of the pandemic lingers as a headwind for the group and its allies in supporting the market.\nIn a monthly report, the Organization of the Petroleum Exporting Countries said demand will rise by 5.89 million barrels per day (bpd) in 2021, or 6.5%, up slightly from last month. But the group cut its forecasts for the first half.\n“Total oil demand is foreseen to reach 96.3 million bpd with most consumption appearing in the second half,” OPEC said in the report.\n“This year’s demand growth will not be able to compensate for the major shortfall from 2020 as mobility is forecast to remain impaired throughout 2021.”\nThe latest forecasts could bolster cautious views among OPEC and its allies, known as OPEC+, on how quickly to unwind more of last year’s record oil output cuts. OPEC+ last week decided to mostly extend current curbs into April.\nOil held onto most of an earlier gain after the report was released, trading close to $69 a barrel. Prices have risen to pre-pandemic highs this month, boosted by hopes of economic recovery and OPEC+ supply restraint.\nOPEC raised its forecast of world economic growth this year to 5.1% from 4.8% as activity accelerates by the end of the first half. Still, it sees the mobility restrictions continuing to dampen oil demand, despite faster growth.\n“Oil-intensive sectors, especially travel and transportation, will remain disproportionately affected, with a larger negative impact on 2020 oil demand and a lower positive contribution to 2021 oil demand, relative to global economic growth,” OPEC said.\nSAUDI DELIVERS CUT\nThe report also showed lower OPEC oil output in February as most OPEC+ members returned to output restraint and Saudi Arabia pledged a voluntary cut of 1 million bpd for February and March.\nOPEC said its February output fell by 650,000 bpd to 24.85 million bpd, driven by the Saudi move. Riyadh told OPEC it made almost all of the reduction, lowering production by 956,000 bpd to 8.147 million bpd.\nSaudi Arabia as part of last week’s OPEC+ decision extended the voluntary cut into April.\nOPEC+ cut supply by a record 9.7 million bpd last year to support the market as demand collapsed. The producers as of February were still withholding about 8.1 million bpd.\nWhile those curbs persist, rivals are boosting supply and OPEC raised its forecast of non-OPEC output growth to almost 1 million bpd led by Canada, the United States, Norway and Brazil - although U.S. shale output is still expected to drop.\nPartly due to the higher non-OPEC supply forecast, OPEC trimmed its estimate of global demand for its crude to 27.3 million bpd this year. This would still allow for higher average OPEC production in 2021.","news_type":1,"symbols_score_info":{"BZmain":0.9,"CLmain":0.9}},"isVote":1,"tweetType":1,"viewCount":797,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":321007401,"gmtCreate":1615382929703,"gmtModify":1704781945088,"author":{"id":"3574683709420484","authorId":"3574683709420484","name":"Baper","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574683709420484","authorIdStr":"3574683709420484"},"themes":[],"htmlText":"Hellooo","listText":"Hellooo","text":"Hellooo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/321007401","repostId":"1128608854","repostType":4,"isVote":1,"tweetType":1,"viewCount":1286,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":323075781,"gmtCreate":1615294789143,"gmtModify":1704780720497,"author":{"id":"3574683709420484","authorId":"3574683709420484","name":"Baper","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574683709420484","authorIdStr":"3574683709420484"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/OGEN\">$Oragenics(OGEN)$</a>?????","listText":"<a href=\"https://laohu8.com/S/OGEN\">$Oragenics(OGEN)$</a>?????","text":"$Oragenics(OGEN)$?????","images":[{"img":"https://static.tigerbbs.com/abfc8778b0fd238b01d7e6f54193391a","width":"1242","height":"2151"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/323075781","isVote":1,"tweetType":1,"viewCount":1262,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":323061904,"gmtCreate":1615290202208,"gmtModify":1704780659952,"author":{"id":"3574683709420484","authorId":"3574683709420484","name":"Baper","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574683709420484","authorIdStr":"3574683709420484"},"themes":[],"htmlText":"Hello","listText":"Hello","text":"Hello","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/323061904","repostId":"1155495533","repostType":4,"isVote":1,"tweetType":1,"viewCount":1320,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":329841830,"gmtCreate":1615224925620,"gmtModify":1704779881415,"author":{"id":"3574683709420484","authorId":"3574683709420484","name":"Baper","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574683709420484","authorIdStr":"3574683709420484"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GME\">$GameStop(GME)$</a>Gme is rising agn","listText":"<a href=\"https://laohu8.com/S/GME\">$GameStop(GME)$</a>Gme is rising agn","text":"$GameStop(GME)$Gme is rising agn","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/329841830","isVote":1,"tweetType":1,"viewCount":934,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":329982871,"gmtCreate":1615198437493,"gmtModify":1704779428427,"author":{"id":"3574683709420484","authorId":"3574683709420484","name":"Baper","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574683709420484","authorIdStr":"3574683709420484"},"themes":[],"htmlText":"??????","listText":"??????","text":"??????","images":[{"img":"https://static.tigerbbs.com/29994c21ce74a3f19972474de7a5ce37","width":"1125","height":"3165"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/329982871","isVote":1,"tweetType":1,"viewCount":1055,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":329986005,"gmtCreate":1615198328507,"gmtModify":1704779426905,"author":{"id":"3574683709420484","authorId":"3574683709420484","name":"Baper","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574683709420484","authorIdStr":"3574683709420484"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/329986005","repostId":"1101320011","repostType":4,"isVote":1,"tweetType":1,"viewCount":714,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":329988586,"gmtCreate":1615198317945,"gmtModify":1704779426098,"author":{"id":"3574683709420484","authorId":"3574683709420484","name":"Baper","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574683709420484","authorIdStr":"3574683709420484"},"themes":[],"htmlText":"Hello","listText":"Hello","text":"Hello","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/329988586","repostId":"1101320011","repostType":4,"isVote":1,"tweetType":1,"viewCount":856,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":361799278,"gmtCreate":1614260217494,"gmtModify":1704769763637,"author":{"id":"3574683709420484","authorId":"3574683709420484","name":"Baper","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574683709420484","authorIdStr":"3574683709420484"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GME\">$GameStop(GME)$</a>Anyone having issue not being able to sell?","listText":"<a href=\"https://laohu8.com/S/GME\">$GameStop(GME)$</a>Anyone having issue not being able to sell?","text":"$GameStop(GME)$Anyone having issue not being able to sell?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":5,"repostSize":0,"link":"https://ttm.financial/post/361799278","isVote":1,"tweetType":1,"viewCount":427,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":386024156,"gmtCreate":1613117606175,"gmtModify":1704878546760,"author":{"id":"3574683709420484","authorId":"3574683709420484","name":"Baper","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574683709420484","authorIdStr":"3574683709420484"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GME\">$GameStop(GME)$</a>Should i sell my GME? 10@150","listText":"<a href=\"https://laohu8.com/S/GME\">$GameStop(GME)$</a>Should i sell my GME? 10@150","text":"$GameStop(GME)$Should i sell my GME? 10@150","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/386024156","isVote":1,"tweetType":1,"viewCount":757,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3545227867848012","authorId":"3545227867848012","name":"芜湖机长","avatar":"https://static.tigerbbs.com/9a3833edd93f904b3905c9925fb85463","crmLevel":1,"crmLevelSwitch":0,"idStr":"3545227867848012","authorIdStr":"3545227867848012"},"content":"If you are willing to wait for months or even years, just to get back the book, don't sell it. If you want to make money, you should know that if you miss something, don't chase it again. It's better to stop loss early and go to the next target","text":"If you are willing to wait for months or even years, just to get back the book, don't sell it. If you want to make money, you should know that if you miss something, don't chase it again. It's better to stop loss early and go to the next target","html":"If you are willing to wait for months or even years, just to get back the book, don't sell it. If you want to make money, you should know that if you miss something, don't chase it again. It's better to stop loss early and go to the next target"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":365457378,"gmtCreate":1614774538094,"gmtModify":1704775042904,"author":{"id":"3574683709420484","authorId":"3574683709420484","name":"Baper","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574683709420484","authorIdStr":"3574683709420484"},"themes":[],"htmlText":"Hello","listText":"Hello","text":"Hello","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/365457378","repostId":"1183651905","repostType":4,"isVote":1,"tweetType":1,"viewCount":740,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":355334406,"gmtCreate":1617027949005,"gmtModify":1704801077052,"author":{"id":"3574683709420484","authorId":"3574683709420484","name":"Baper","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574683709420484","authorIdStr":"3574683709420484"},"themes":[],"htmlText":"Hello","listText":"Hello","text":"Hello","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/355334406","repostId":"1161842003","repostType":4,"repost":{"id":"1161842003","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1617027210,"share":"https://ttm.financial/m/news/1161842003?lang=en_US&edition=fundamental","pubTime":"2021-03-29 22:13","market":"us","language":"en","title":"RLX rose more than 11%","url":"https://stock-news.laohu8.com/highlight/detail?id=1161842003","media":"Tiger Newspress","summary":"(March 29) Days ago, China's Ministry of Industry and Information Technology posted an update that i","content":"<p>(March 29)&nbsp;Days ago, China's Ministry of Industry and Information Technology posted an update that indicated tightened regulations for the cigarette industry will also be applicable to the electronic cigarette sector.</p><p><img src=\"https://static.tigerbbs.com/30359e8f873abb547c80ebb67d0b3d90\" tg-width=\"642\" tg-height=\"512\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RLX rose more than 11%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRLX rose more than 11%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-03-29 22:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(March 29)&nbsp;Days ago, China's Ministry of Industry and Information Technology posted an update that indicated tightened regulations for the cigarette industry will also be applicable to the electronic cigarette sector.</p><p><img src=\"https://static.tigerbbs.com/30359e8f873abb547c80ebb67d0b3d90\" tg-width=\"642\" tg-height=\"512\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/9bc4ee269ad9cff7441dc3605e3bc69a","relate_stocks":{"RLX":"雾芯科技"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1161842003","content_text":"(March 29) Days ago, China's Ministry of Industry and Information Technology posted an update that indicated tightened regulations for the cigarette industry will also be applicable to the electronic cigarette sector.","news_type":1,"symbols_score_info":{"RLX":0.9}},"isVote":1,"tweetType":1,"viewCount":2978,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":322487202,"gmtCreate":1615820904706,"gmtModify":1704787125354,"author":{"id":"3574683709420484","authorId":"3574683709420484","name":"Baper","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574683709420484","authorIdStr":"3574683709420484"},"themes":[],"htmlText":"Hiello","listText":"Hiello","text":"Hiello","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/322487202","repostId":"1110886827","repostType":4,"repost":{"id":"1110886827","kind":"news","pubTimestamp":1615819641,"share":"https://ttm.financial/m/news/1110886827?lang=en_US&edition=fundamental","pubTime":"2021-03-15 22:47","market":"us","language":"en","title":"Why Eli Lilly's Successful Alzheimer's Disease Study Was So Disappointing","url":"https://stock-news.laohu8.com/highlight/detail?id=1110886827","media":"Motley Fool","summary":"Eli Lilly's latest Alzheimer's disease candidate is a terrific success and a disappointing flop at t","content":"<blockquote><b>Eli Lilly's latest Alzheimer's disease candidate is a terrific success and a disappointing flop at the same time.</b></blockquote><p>Attention for<b>Eli Lilly</b>(NYSE:LLY)has been blowing up since the company announced success for its experimental new Alzheimer's disease drug. Unfortunately, the results strongly suggest that Eli Lilly and<b>Biogen</b>(NASDAQ:BIIB)have a lot more work to do.</p><p>How can a clinical trial that succeeded also foreshadow a slow-motion trainwreck? Strap in for some nuance.</p><p><b>Technically a success</b></p><p>The phase 2 Trailblazer trial rounded up hundreds of people with early stage Alzheimer's disease and treated them with either a placebo or donanemab to see if the experimental antibody could prevent their disease from getting worse.</p><p>Earlier this year, Eli Lilly sparked a lot of hope for donanemab by telling everybody the Trailblazer trial met its main goal. That goal was a significantly improved score on a relatively new test to measure patients' cognitive and functional abilities. After treating 257 patients for 76 weeks, test scores for those given a placebo deteriorated 46% further than test scores for patients randomized to receive donanemab.</p><p>Donanemab works in the brain to reduce the formation of dangerous plaques made of amyloid protein fragments. After 76 weeks, comparing brain scans also showed huge amyloid plaque reductions for those given donanemab compared to those given a placebo.</p><p><b>Why donanemab disappointed</b></p><p>Donanemab significantly slowed patients' rate of decline on the integrated Alzheimer's disease rating scale. The iADRS combines a commonly used cognition test with a test that measures AD patients' ability to function as adults.</p><p>The FDA has never reviewed an application for a potential new Alzheimer's disease drug based on a successful iADRS score. That could be a big problem for Eli Lilly because the Trailblazer study assaulted trial participants with a battery of different tests and the iADRS was the only measurement in which donanemab provided a statistically significant benefit.</p><p>Moreover, the benefit wasn't any better than Eli Lilly reported for solanezumab years ago. This twice-failed amyloid remover from Eli Lilly couldn't meet its primary endpoint in phase 3 trials, but it did lead to significantly improved iADRS scores.</p><p><b>This isn't working</b></p><p>Donanemab is similar to solanezumab, except it appears far more effective at removing amyloid deposits and preventing their formation. This is why Eli Lilly was eager to make the iADRS test aprimary endpointfor donanemab trials, and extra careful to select trial volunteers that already had lots of amyloid deposits to remove.</p><p>If the donanemab program went according to plan, more amyloid to remove, plus a better drug to remove it should have led to an iADRS score benefit that rang clear as a bell. What happened was far less satisfying.</p><p>Patients began the Trailblazer trial with average iADRS scores of 106 points out of a potential 141 points. After 76 weeks, those given a placebo averaged just 3.2 points lower than those given donanemab.</p><p>Unfortunately, those given donanemab didn't improve or even hold steady. In fact, their average scores fell by 6.9 points.</p><p><b>What's next</b></p><p>The Trailblazer trial is another clear sign that removing amyloid deposits isn't a surefire way to stop the progression of AD, but it appears to work well for some. Decades from now we'll probably think of AD as a collection of different diseases, just one or two of which respond to drugs like donanemab on their own. In the meantime, U.S. regulators have a controversial decision to make that could help us understand the connection between amyloid knockdowns and the disease.</p><p>The FDA iseager to approvean amyloid-clearing AD drug from Biogen called aducanumab even though independent experts unanimously agree that pivotal trial results didn't show evidence of a benefit. If approved, widespread adoption of Biogen's drug could elucidate just which AD patients respond well to amyloid knockdowns and which don't. The line between Biogen's and Eli Lilly's attempts to treat AD isn't a straight one, but donanemab's future depends on the FDA's willingness to bend the rules for aducanumab.</p><p>Alzheimer's disease affects one out of nine adults over the age of 65 and a dearth of available treatments means the first one will become one of the top-selling drugs of its time. With such an enormous pot of gold at the end of this rainbow, we can't fault Eli Lilly for making further attempts with donanemab. Unfortunately, its chances of success don't look very good.</p><p>Lilly dipped more than 8%&nbsp;in&nbsp;Monday&nbsp;trading.<img src=\"https://static.tigerbbs.com/d7574b908a909fcd58830836a11eb2fc\" tg-width=\"724\" tg-height=\"495\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Eli Lilly's Successful Alzheimer's Disease Study Was So Disappointing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Eli Lilly's Successful Alzheimer's Disease Study Was So Disappointing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-15 22:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/03/15/eli-lilly-reports-underwhelming-alzheimers-disease/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Eli Lilly's latest Alzheimer's disease candidate is a terrific success and a disappointing flop at the same time.Attention forEli Lilly(NYSE:LLY)has been blowing up since the company announced success...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/15/eli-lilly-reports-underwhelming-alzheimers-disease/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来"},"source_url":"https://www.fool.com/investing/2021/03/15/eli-lilly-reports-underwhelming-alzheimers-disease/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1110886827","content_text":"Eli Lilly's latest Alzheimer's disease candidate is a terrific success and a disappointing flop at the same time.Attention forEli Lilly(NYSE:LLY)has been blowing up since the company announced success for its experimental new Alzheimer's disease drug. Unfortunately, the results strongly suggest that Eli Lilly andBiogen(NASDAQ:BIIB)have a lot more work to do.How can a clinical trial that succeeded also foreshadow a slow-motion trainwreck? Strap in for some nuance.Technically a successThe phase 2 Trailblazer trial rounded up hundreds of people with early stage Alzheimer's disease and treated them with either a placebo or donanemab to see if the experimental antibody could prevent their disease from getting worse.Earlier this year, Eli Lilly sparked a lot of hope for donanemab by telling everybody the Trailblazer trial met its main goal. That goal was a significantly improved score on a relatively new test to measure patients' cognitive and functional abilities. After treating 257 patients for 76 weeks, test scores for those given a placebo deteriorated 46% further than test scores for patients randomized to receive donanemab.Donanemab works in the brain to reduce the formation of dangerous plaques made of amyloid protein fragments. After 76 weeks, comparing brain scans also showed huge amyloid plaque reductions for those given donanemab compared to those given a placebo.Why donanemab disappointedDonanemab significantly slowed patients' rate of decline on the integrated Alzheimer's disease rating scale. The iADRS combines a commonly used cognition test with a test that measures AD patients' ability to function as adults.The FDA has never reviewed an application for a potential new Alzheimer's disease drug based on a successful iADRS score. That could be a big problem for Eli Lilly because the Trailblazer study assaulted trial participants with a battery of different tests and the iADRS was the only measurement in which donanemab provided a statistically significant benefit.Moreover, the benefit wasn't any better than Eli Lilly reported for solanezumab years ago. This twice-failed amyloid remover from Eli Lilly couldn't meet its primary endpoint in phase 3 trials, but it did lead to significantly improved iADRS scores.This isn't workingDonanemab is similar to solanezumab, except it appears far more effective at removing amyloid deposits and preventing their formation. This is why Eli Lilly was eager to make the iADRS test aprimary endpointfor donanemab trials, and extra careful to select trial volunteers that already had lots of amyloid deposits to remove.If the donanemab program went according to plan, more amyloid to remove, plus a better drug to remove it should have led to an iADRS score benefit that rang clear as a bell. What happened was far less satisfying.Patients began the Trailblazer trial with average iADRS scores of 106 points out of a potential 141 points. After 76 weeks, those given a placebo averaged just 3.2 points lower than those given donanemab.Unfortunately, those given donanemab didn't improve or even hold steady. In fact, their average scores fell by 6.9 points.What's nextThe Trailblazer trial is another clear sign that removing amyloid deposits isn't a surefire way to stop the progression of AD, but it appears to work well for some. Decades from now we'll probably think of AD as a collection of different diseases, just one or two of which respond to drugs like donanemab on their own. In the meantime, U.S. regulators have a controversial decision to make that could help us understand the connection between amyloid knockdowns and the disease.The FDA iseager to approvean amyloid-clearing AD drug from Biogen called aducanumab even though independent experts unanimously agree that pivotal trial results didn't show evidence of a benefit. If approved, widespread adoption of Biogen's drug could elucidate just which AD patients respond well to amyloid knockdowns and which don't. The line between Biogen's and Eli Lilly's attempts to treat AD isn't a straight one, but donanemab's future depends on the FDA's willingness to bend the rules for aducanumab.Alzheimer's disease affects one out of nine adults over the age of 65 and a dearth of available treatments means the first one will become one of the top-selling drugs of its time. With such an enormous pot of gold at the end of this rainbow, we can't fault Eli Lilly for making further attempts with donanemab. Unfortunately, its chances of success don't look very good.Lilly dipped more than 8% in Monday trading.","news_type":1,"symbols_score_info":{"LLY":0.9}},"isVote":1,"tweetType":1,"viewCount":3382,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":382317395,"gmtCreate":1613362762217,"gmtModify":1704880083033,"author":{"id":"3574683709420484","authorId":"3574683709420484","name":"Baper","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574683709420484","authorIdStr":"3574683709420484"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/HCMC\">$Healthier Choices Management Corp.(HCMC)$</a>Tuesday to the moon!!!???","listText":"<a href=\"https://laohu8.com/S/HCMC\">$Healthier Choices Management Corp.(HCMC)$</a>Tuesday to the moon!!!???","text":"$Healthier Choices Management Corp.(HCMC)$Tuesday to the moon!!!???","images":[{"img":"https://static.tigerbbs.com/a2b5d287958d3890dc59fa8e53e6a720","width":"1242","height":"2151"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/382317395","isVote":1,"tweetType":1,"viewCount":1544,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3573365374507012","authorId":"3573365374507012","name":"tfook","avatar":"https://static.tigerbbs.com/56ad98b4b5d7bd55ea1f263e4e4af301","crmLevel":11,"crmLevelSwitch":0,"idStr":"3573365374507012","authorIdStr":"3573365374507012"},"content":"it will rise, don't worry","text":"it will rise, don't worry","html":"it will rise, don't worry"},{"author":{"id":"3574683709420484","authorId":"3574683709420484","name":"Baper","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"idStr":"3574683709420484","authorIdStr":"3574683709420484"},"content":"Will be buying the dip tomorrow.","text":"Will be buying the dip tomorrow.","html":"Will be buying the dip tomorrow."}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":386268755,"gmtCreate":1613186007877,"gmtModify":1704879312999,"author":{"id":"3574683709420484","authorId":"3574683709420484","name":"Baper","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574683709420484","authorIdStr":"3574683709420484"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GME\">$GameStop(GME)$</a>Happy New Year Apes.&nbsp;","listText":"<a href=\"https://laohu8.com/S/GME\">$GameStop(GME)$</a>Happy New Year Apes.&nbsp;","text":"$GameStop(GME)$Happy New Year Apes.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/386268755","isVote":1,"tweetType":1,"viewCount":1108,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":360021879,"gmtCreate":1613798158491,"gmtModify":1704885168722,"author":{"id":"3574683709420484","authorId":"3574683709420484","name":"Baper","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574683709420484","authorIdStr":"3574683709420484"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GARB\">$Garb Oil &amp; Power Corp.(GARB)$</a>Now is the perfect chance to enter before its too late","listText":"<a href=\"https://laohu8.com/S/GARB\">$Garb Oil &amp; Power Corp.(GARB)$</a>Now is the perfect chance to enter before its too late","text":"$Garb Oil & Power Corp.(GARB)$Now is the perfect chance to enter before its too late","images":[{"img":"https://static.tigerbbs.com/da7fb85b9ea25b7edbff5e844d3bfbcf","width":"1242","height":"2151"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/360021879","isVote":1,"tweetType":1,"viewCount":750,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3547861761357411","authorId":"3547861761357411","name":"B_B_king","avatar":"https://static.tigerbbs.com/8d101799ebfbc9602c2bb880444ff9b8","crmLevel":2,"crmLevelSwitch":0,"idStr":"3547861761357411","authorIdStr":"3547861761357411"},"content":"This company has cooperation with a domestic factory. Which one has not been found yet. At present, the official homepage cannot be accessed, and another homepage can still be accessed. The last message of the official Twitter is August 5, 2019. I bought a total of 500,000 lottery positions","text":"This company has cooperation with a domestic factory. Which one has not been found yet. At present, the official homepage cannot be accessed, and another homepage can still be accessed. The last message of the official Twitter is August 5, 2019. I bought a total of 500,000 lottery positions","html":"This company has cooperation with a domestic factory. Which one has not been found yet. At present, the official homepage cannot be accessed, and another homepage can still be accessed. The last message of the official Twitter is August 5, 2019. I bought a total of 500,000 lottery positions"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":386738861,"gmtCreate":1613271735853,"gmtModify":1704879667305,"author":{"id":"3574683709420484","authorId":"3574683709420484","name":"Baper","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574683709420484","authorIdStr":"3574683709420484"},"themes":[],"htmlText":"To the moon soon!!!","listText":"To the moon soon!!!","text":"To the moon soon!!!","images":[{"img":"https://static.tigerbbs.com/84a6499fbdffa6a53bfbfa3819e25750","width":"1125","height":"3114"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":1,"link":"https://ttm.financial/post/386738861","isVote":1,"tweetType":1,"viewCount":628,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":386102584,"gmtCreate":1613141236848,"gmtModify":1704878854705,"author":{"id":"3574683709420484","authorId":"3574683709420484","name":"Baper","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574683709420484","authorIdStr":"3574683709420484"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a>Better don’t buy this stock. Its a gamble, too risky....&nbsp;","listText":"<a href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a>Better don’t buy this stock. Its a gamble, too risky....&nbsp;","text":"$Histogenics(OCGN)$Better don’t buy this stock. Its a gamble, too risky....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/386102584","isVote":1,"tweetType":1,"viewCount":1393,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}